Design and synthesis of amino-substituted N-arylpiperidinyl-based inhibitors of the (immuno)proteasome
References
- R. Raynes, L. C. D. Pomatto and K. J. A. Davies, Degradation of oxidized proteins by the protea-some: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways, Mol. Aspects Med. 50 (2016) 41–55; https://doi.org/10.1016/j.mam.2016.05.001
- I. Sahu and M. H. Glickman, Proteasome in action: substrate degradation by the 26S proteasome, Biochem. Soc. Trans. 49(2) (2021) 629–644; https://doi.org/10.1042/BST20200382
- D. Voges, P. Zwickl and W. Baumeister, The 26S proteasome: a molecular machine designed for controlled proteolysis, Annu. Rev. Biochem. 68 (1999) 1015–1068; https://doi.org/10.1146/annurev.biochem.68.1.1015
- G. A. Collins and A. L. Goldberg, The logic of the 26S proteasome, Cell 169 (2017) 792–806; https://doi.org/10.1016/j.cell.2017.04.023
- J. A. M. Bard, E. A. Goodall, E. R. Greene, E. Jonsson, K. C. Dong and A. Martin, Structure and function of the 26S proteasome, Annu. Rev. Biochem. 87 (2018) 697–724; https://doi.org/10.1146/annurev-biochem-062917-011931
- F. Türker, E. K. Cook and S. S. Margolis, The proteasome and its role in the nervous system, Cell Chem. Biol. 28 (2021) 903–917; https://doi.org/10.1016/j.chembiol.2021.04.003
- S. A. Bhat, Z. Vasi, R. Adhikari, A. Gudur, A. Ali, L. Jiang, R. Ferguson, D. Liang and S. Kuchay, Ubiquitin proteasome system in immune regulation and therapeutics, Curr. Opin. Pharmacol. 67 (2022) Article ID 102310; https://doi.org/10.1016/j.coph.2022.102310
- L. A. Passmore and D. Barford, Getting into position: the catalytic mechanisms of protein ubiquitylation, Biochem. J. 379(3) (2004) 513–525; https://doi.org/10.1042/BJ20040198
- S. H. Lecker, A. L. Goldberg and W. E. Mitch, Protein degradation by the ubiquitin–proteasome pathway in normal and disease states, J. Am. Soc. Nephrol. 17(7) (2006) 1807–1819; https://doi.org/10.1681/ASN.2006010083
- G. Kleiger and T. Mayor, Perilous journey: a tour of the ubiquitin-proteasome system, Trends Cell Biol. 24(6) (2014) 352–359; https://doi.org/10.1016/j.tcb.2013.12.003
- J. Adams, The proteasome: structure, function, and role in the cell, Cancer Treat. Rev. 29 (2003) 3–9; https://doi.org/10.1016/S0305-7372(03)00081-1
- M. Groettrup, C. J. Kirk and M. Basler, Proteasomes in immune cells: more than peptide producers?, Nat. Rev. Immunol. 10 (2010) 73–78; https://doi.org/10.1038/nri2687
- L. Bedford, S. Paine, P. W. Sheppard, R. J. Mayer and J. Roelofs, Assembly, structure, and function of the 26S proteasome, Trends Cell Biol. 20(7) (2010) 391–401; https://doi.org/10.1016/j.tcb.2010.03.007
- L. Budenholzer, C. L. Cheng, Y. Li and M. Hochstrasser, Proteasome structure and assembly, J. Mol. Biol. 429(22) (2017) 3500–3524; https://doi.org/10.1016/j.jmb.2017.05.027
- T. A. Thibaudeau and D. M. Smith, A practical review of proteasome pharmacology, Pharmacol. Rev. 71(2) (2019) 170–197; https://doi.org/10.1124/pr.117.015370
- E. Ogorevc, E. S. Schiffrer, I. Sosič and S. Gobec, A patent review of immunoproteasome inhibitors, Expert Opin. Ther. Pat. 28(7) (2018) 517–540; https://doi.org/10.1080/13543776.2018.1484904
- M. Groettrup, S. Khan, K. Schwarz and G. Schmidtke, Interferon-γ inducible exchanges of 20S proteasome active site subunits: Why?, Biochimie 83(3–4) (2001) 367–372; https://doi.org/10.1016/S0300-9084(01)01251-2
- G. Kaur and S. Batra, Emerging role of immunoproteasomes in pathophysiology, Immunol. Cell Biol. 94(9) (2016) 812–820; https://doi.org/10.1038/icb.2016.50
- A. Mani and E. P. Gelmann, The ubiquitin-proteasome pathway and its role in cancer, J. Clin. Oncol. 23(21) (2005) 4776–4789; https://doi.org/10.1200/JCO.2005.05.081
- D. J. Kuhn and R. Z. Orlowski, The immunoproteasome as a target in hematologic malignancies, Semin. Hematol. 49(3) (2012) 258–262; https://doi.org/10.1053/j.seminhematol.2012.04.003
- M. Schmidt and D. Finley, Regulation of proteasome activity in health and disease, Biochim. Biophys. Acta BBA – Mol. Cell Res. 1843(1) (2014) 13–25; https://doi.org/10.1016/j.bbamcr.2013.08.012
- J. E. Park, Z. Miller, Y. Jun, W. Lee and K. B. Kim, Next-generation proteasome inhibitors for cancer therapy, Transl. Res. 198 (2018) 1–16; https://doi.org/10.1016/j.trsl.2018.03.002
- V. T. de M. Hungria, E. de Q. Crusoé, R. I. Bittencourt, A. Maiolino, R. J. P. Magalhães, J. do N. Sobrinho, J. V. Pinto, R. C. Fortes, E. de S. Moreira and P. Y. Tanaka, New proteasome inhibitors in the treatment of multiple myeloma, Hematol. Transfus. Cell Ther. 41(1) (2019) 76–83; https://doi.org/10.1016/j.htct.2018.07.003
- E. M. Huber and M. Groll, Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development, Angew. Chem. Int. Ed. 51(35) (2012) 8708–8720; https://doi.org/10.1002/anie.201201616
- A. F. Kisselev and M. Groettrup, Subunit specific inhibitors of proteasomes and their potential for immunomodulation, Curr. Opin. Chem. Biol. 23 (2014) 16–22; https://doi.org/10.1016/j.cbpa.2014.08.012
- P. M. Cromm and C. M. Crews, The proteasome in modern drug discovery: second life of a highly valuable drug target, ACS Cent. Sci. 3 (2017) 830–838; https://doi.org/10.1021/acscentsci.7b00252
- B. L. Zerfas, M. E. Maresh and D. J. Trader, The immunoproteasome: an emerging target in cancer and autoimmune and neurological disorders, J. Med. Chem. 63(5) (2020) 1841–1858; https://doi.org/10.1021/acs.jmedchem.9b01226
- R. Ettari, M. Zappalà, S. Grasso, C. Musolino, V. Innao and A. Allegra, Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma, Pharmacol. Ther. 182 (2018) 176–192; https://doi.org/10.1016/j.pharmthera.2017.09.001
- D. J. Sherman and J. Li, Proteasome inhibitors: harnessing proteostasis to combat disease, Molecules 25(3) (2020) Article ID 671 (30 pages); https://doi.org/10.3390/molecules25030671
- E. M. Huber and M. Groll, A nut for every bolt: subunit-selective inhibitors of the immunoproteasome and their therapeutic potential, Cells 10(8) (2021) Article ID 1929 (21 pages); https://doi.org/10.3390/cells10081929
- G. R. Tundo, P. Cascio, D. Milardi, A. M. Santoro, G. Graziani, P. M. Lacal, A. Bocedi, F. Oddone, M. Parravano, A. Coletta, M. Coletta and D. Sbardella, Targeting immunoproteasome in neurode-generation: A glance to the future, Pharmacol. Ther. 241 (2023) Article ID 108329; https://doi.org/10.1016/j.pharmthera.2022.108329
- I. Sosič, M. Gobec, B. Brus, D. Knez, M. Živec, J. Konc, S. Lešnik, M. Ogrizek, A. Obreza, D. Žigon, D. Janežič, I. Mlinarič-Raščan and S. Gobec, Nonpeptidic selective inhibitors of the chymotrypsin-like (β5i) subunit of the immunoproteasome, Angew. Chem. Int. Ed. 55(19) (2016) 5745–5748; https://doi.org/10.1002/anie.201600190
- E. S. Schiffrer, I. Sosič, A. Šterman, J. Mravljak, I. M. Raščan, S. Gobec and M. Gobec, A focused structure-activity relationship study of psoralen-based immunoproteasome inhibitors, MedChem-Comm 10 (2019) 1958–1965; https://doi.org/10.1039/C9MD00365G
- E. S. Schiffrer, M. Proj, M. Gobec, L. Rejc, A. Šterman, J. Mravljak, S. Gobec and I. Sosič, Synthesis and biochemical evaluation of warhead-decorated psoralens as (immuno)proteasome inhibitors, Molecules 26(2) (2021) Article ID 356 (18 pages); https://doi.org/10.3390/molecules26020356
- A. P. Bento, A. Gaulton, A. Hersey, L. J. Bellis, J. Chambers, M. Davies, F. A. Krüger, Y. Light, L. Mak, S. McGlinchey, M. Nowotka, G. Papadatos, R. Santos and J. P. Overington, The ChEMBL bioactivity database: an update, Nucleic Acids Res. 42 (2014) D1083–D1090; https://doi.org/10.1093/nar/gkt1031
- L.-H. Wang, A. Evers, P. Monecke and T. Naumann, Ligand based lead generation – considering chemical accessibility in rescaffolding approaches via BROOD, J. Cheminf. 4(Suppl. 1) (2012) Article ID O20 (1 page); https://doi.org/10.1186/1758-2946-4-S1-O20
- B. J. Neves, R. V. Bueno, R. C. Braga and C. H. Andrade, Discovery of new potential hits of Plasmodium falciparum enoyl-ACP reductase through ligand- and structure-based drug design approaches, Bioorg. Med. Chem. Lett. 23(8) (2013) 2436–2441; https://doi.org/10.1016/j.bmcl.2013.02.006
- A. Obreza, K. Grabrijan, S. Kadić, F. J. de L. Garrido, I. Sosič, S. Gobec and M. Jukič, Chlorocarbonylsulfenyl chloride cyclizations towards piperidin-3-yl-oxathiazol-2-ones as potential covalent inhibitors of threonine proteases, Acta Chim. Slov. 64(4) (2017) 771–781; https://doi.org/10.17344/acsi.2017.3883
- A. P. Hill and R. J. Young, Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity, Drug Discov. Today 15 (15–16) (2010) 648–655; https://doi.org/10.1016/j.drudis.2010.05.016
- E. M. Huber, M. Basler, R. Schwab, W. Heinemeyer, C. J. Kirk, M. Groettrup and M. Groll, Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity, Cell 148(4) (2012) 727–738; https://doi.org/10.1016/j.cell.2011.12.030
- C. Dubiella, H. Cui, M. Gersch, A. J. Brouwer, S. A. Sieber, A. Krüger, R. M. J. Liskamp and M. Groll, selective inhibition of the immunoproteasome by ligand-induced crosslinking of the active site, Angew. Chem. Int. Ed. 53(44) (2014) 11969–11973; https://doi.org/10.1002/anie.201406964
- L. Kollár, M. Gobec, B. Szilágyi, M. Proj, D. Knez, P. Ábrányi-Balogh, L. Petri, T. Imre, D. Bajusz, G. G. Ferenczy, S. Gobec, G. M. Keserű and I. Sosič, Discovery of selective fragment-sized immunoproteasome inhibitors, Eur. J. Med. Chem. 219 (2021) Article ID 113455; https://doi.org/10.1016/j.ejmech.2021.113455
- L. Kollár, M. Gobec, M. Proj, L. Smrdel, D. Knez, T. Imre, Á. Gömöry, L. Petri, P. Ábrányi-Balogh, D. Csányi, G. G. Ferenczy, S. Gobec, I. Sosič and G. M. Keserű, fragment-sized and bidentate (immuno)proteasome inhibitors derived from cysteine and threonine targeting warheads, Cells 10(12) (2021) Article ID 3431 (19 pages); https://doi.org/10.3390/cells10123431
- R. Ettari, C. Cerchia, S. Maiorana, M. Guccione, E. Novellino, A. Bitto, S. Grasso, A. Lavecchia and M. Zappalà, development of novel amides as noncovalent inhibitors of immunoproteasomes, ChemMedChem 14(8) (2019) 842–852; https://doi.org/10.1002/cmdc.201900028
Language: English
Page range: 441 - 456
Accepted on: Jul 2, 2023
Published on: Sep 14, 2023
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2023 Martina Gobec, Aleš Obreza, Marko Jukič, Ana Baumgartner, Nja Mihelčič, Špela Potočnik, Julija Virant, Irena Mlinarič, Raščan Stanislav, Gobec Izidor Sosič, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.